A team of researchers has developed a CRISPR-based gene editor, C-to-G Base Editor (CGBE), to correct mutations that cause genetic disorders. One in seventeen people in the world suffers from some type of genetic disorder.
“The CGBE gene editor is a ground-breaking invention that for the first time, directly converts C to G in genes, which potentially opens up treatment avenues for a substantial fraction of genetic disorders associated with single-nucleotide mutations,” said author Chew Wei Leong, Senior Research Scientist at Genome Institute of Singapore.
Follow NewsGram on LinkedIn to know what’s happening around the world.
The most common mutation by far is the single-based substitution, in which a single base in the DNA (such as G) is replaced by another base (such as C) according to the study, published in Nature Communications. Countless cystic fibrosis patients worldwide have C instead of G, leading to defective proteins that cause the genetic disease. In another case, replacing A with T in hemoglobin causes sickle cell anemia.
To fix these substitutions, the team invented a CRISPR-based gene editor that precisely changes the defective C within the genome to the desired G. This C-to-G base editor (CGBE) invention opens up treatment options for approximately 40 percent of the single-base substitutions that are associated with human diseases such as the aforementioned cystic fibrosis, cardiovascular diseases, musculoskeletal diseases, and neurological disorders.
ALSO READ: New Genetic Disorder Found in Human Patient
The CGBE editor advances the widely adopted CRISPR-Cas9 technology to enable molecular surgery on the human genome. The CRISPR-Cas9 technology is routinely used to disrupt target genes, but it is inefficient when a precise change to particular sequences is desired. The CGBE editor resolves a key aspect of this challenge by enabling efficient and precise genetic changes.
CGBE consists of three parts — a modified CRISPR-Cas9 will pinpoint the mutant gene and focus the entire editor on that gene; a deaminase (an enzyme that removes the amino group from a compound) will then target the defective C, and mark it for replacement, and; finally, a protein will initiate cellular mechanisms to replace that defective C with a G. This enables a previously unachievable direct conversion from C to G, correcting the mutation and, consequently, treating the genetic disorder. (IANS/SP)